Amiodarone Indications
Amiodarone is FDA-approved exclusively for life-threatening ventricular arrhythmias (ventricular fibrillation and hemodynamically unstable ventricular tachycardia) refractory to other therapy, though it is widely used off-label for atrial fibrillation in patients with structural heart disease. 1
FDA-Approved Indications
Life-threatening ventricular arrhythmias are the only FDA-approved indication:
- Ventricular fibrillation (VF) - for initiation of treatment and prophylaxis of frequently recurring VF 1
- Hemodynamically unstable ventricular tachycardia (VT) - in patients refractory to other therapy 1
- Secondary prevention - in patients who have survived sustained ventricular tachyarrhythmias, particularly those with left ventricular dysfunction 2, 3
- Adjunct therapy with ICDs - to reduce frequency of appropriate shocks from recurrent ventricular arrhythmias 3
Guideline-Supported Off-Label Uses
Atrial fibrillation represents the most common off-label indication, but only as a second-line agent:
- Atrial fibrillation with structural heart disease - recommended as a second-line agent when beta-blockers, calcium channel blockers, or class IC agents have failed or are contraindicated 3
- Atrial fibrillation with heart failure - amiodarone is more effective than sotalol or propafenone in maintaining sinus rhythm (62% vs 23% at one year) 2, 4
- Rate control in atrial fibrillation - when left ventricular function is severely impaired and digitalis has been ineffective 5
Emergency cardiac arrest situations:
- Refractory VF/pulseless VT - 300 mg IV/IO bolus after failed defibrillation and epinephrine, with possible second 150 mg dose 3, 6
- Hemodynamically stable monomorphic VT - when immediate cardioversion is not required 6
When Amiodarone Should NOT Be Used
Critical contraindications that must be respected:
- Primary prevention of sudden death - ICDs are more effective; amiodarone is not recommended for this indication 3
- Asymptomatic atrial fibrillation with adequate rate control - long-term therapy is not justified if anticoagulation and rate-control strategies provide satisfactory symptom improvement 3
- Asymptomatic premature ventricular complexes or non-sustained VT - routine treatment is not justified 3
- Second- or third-degree AV block without functioning pacemaker - absolute contraindication 1
- Patients ≥75 years as first-line therapy - classified as potentially inappropriate medication due to high toxicity risk (up to 93% experience side effects, 15-19% require discontinuation) 3
Special Population Considerations
Structural heart disease makes amiodarone uniquely suitable:
- Coronary artery disease - amiodarone can be safely used, unlike class IC agents which are contraindicated 3
- Heart failure with reduced ejection fraction - amiodarone has neutral effects on mortality, making it one of few safe antiarrhythmics in this population 3
- Post-myocardial infarction - safe to use when other agents carry prohibitive risk 7
Pregnancy and lactation:
- Category D drug - contraindicated in pregnant and breastfeeding women due to reports of congenital goiter, hypothyroidism, and hyperthyroidism 1, 8
Common Clinical Pitfalls
Avoid these frequent errors:
- Using amiodarone as first-line for atrial fibrillation without structural heart disease - flecainide, propafenone, or dronedarone should be tried first 3
- Prescribing without considering the 58-day half-life - adverse effects persist for months after discontinuation, complicating management 2, 3
- Failing to reduce concomitant medications - digoxin dose must be cut by 50% and warfarin by 30-50% when starting amiodarone 3
- Inadequate monitoring protocols - thyroid and liver function must be checked every 6 months, baseline pulmonary function tests and chest X-ray are mandatory 3